Inflammation/Immunology

T3/OVA is an antigen-adjuvant conjugate formed by conjugating T3 (thyroxine) with ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonal antibody. SHR-1703 can selectively recognize and bind to IL-5, blocking the binding of IL-5 to the α chain of the receptor on the surface of eosinophils, thereby inhibiting the proliferation, activation, and migration of eosinophils, and ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 can be used in the research of eosinophil-related diseases, such as eosinophilic asthma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

PROTAC NLRP3 degrader-1 is a PROTAC degrader targeting NLRP3. PROTAC NLRP3 degrader-1 recruits VHL E3 ubiquitin ligase to form a ternary complex with NLRP3, inducing VHL-dependent ubiquitination and proteasomal degradation of the inflammasome sensor NLRP3. PROTAC NLRP3 degrader-1 reduces IL-1β release. PROTAC NLRP3 degrader-1 can be used for research on NLRP3-related inflammation, metabolic inflammation, and cancer.

PknB-IN-1 (Compound 2) is a protein kinase B (PknB) inhibitor (IC₅₀=14.4 μM). PknB-IN-1 shows anti-mycobacterial activity, can inhibit M. tuberculosis H37Rv strain growth (MIC=6.2 μg/mL).

K-80001 is an RXRα-binder and COX-1/2 inhibitor, with IC₅₀s of with an IC₅₀ of 82.9μM, 3.4μM, 1.2μM for RXRα, COX-1 and COX-2, respectively.

Colchiceine (Standard) is the analytical standard of Colchiceine. This product is intended for research and analytical applications. Colchiceine is one of several metabolites of the anti-gout medication Colchicine (HY-16569). Colchicine is a tubulin inhibitor and a microtubule disrupting agent, and may protect rats from developing liver injury and fibrosis.

Ginsenoside Rd (Standard) is the analytical standard of Ginsenoside Rd. This product is intended for research and analytical applications. Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca2+ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.

RAF-IN-2 is a RAF inhibitor. RAF-IN-2 can be used for proliferative diseases such as leukemia, psoriasis and fibrosis research.

Anti-inflammatory agent 31 (enone 17) is a kind of andrographolide derivatives, is a anti-inflammatory agent. Anti-inflammatory agent 31 inhibits NF-κB activation by upstream blockade of PI3K/Akt and ERK1/2 MAPK activation. Anti-inflammatory agent 31 shows recovery effective of the intracellular GSH levels and protective effect on liver.

RE-33 is an analgesic compound. RE-33 has blood brain barrier penetration ability.

AZ-DF 265 is a hypoglycemic agent that stimulates insulin release. AZ-DF-265 inhibits ATP-sensitive potassium channels, activates voltage-dependent calcium channels, allows calcium ion influx, and ultimately promotes insulin secretion. AZ-DF 265 can be used in diabetes-related research.

Sargachromanol E is an apoptosis inducer, anti-inflammatory agent, and anti-aging agent. Sargachromanol E activates caspase-3, mediates PARP cleavage, downregulates Bcl-xL and upregulates Bax levels, and drives sub-G1 phase cell cycle arrest, inhibits LPS-induced COX-2 and iNOS transcription and expression (NO: IC₅₀ = 6.99 μg/mL), reduces p38 MAPK and ERK1/2 phosphorylation levels, and suppresses the release of pro-inflammatory mediators such as TNF-α, IL-1β, and prostaglandin E₂ (PGE₂). Sargachromanol E can be used for research on skin aging, leukemia, oral squamous cell carcinoma, and inflammation-related studies.

Vitacoxib is an Imidazole (HY-D0837) derivative, selective COX-2 inhibitor, anti-inflammatory agent. Vitacoxib can be used in the research of inflammatory diseases, pain and fever.

PF-03475952 is a fully human IgG2 monoclonal antibody targeting CD44. PF-03475952 binds an epitope in CD44’s constant exons, blocks CD44-hyaluronic acid interaction, reduces cell surface CD44, and does not cross-react with rodent CD44 or LYVE-1. PF-03475952 induces cancer cell apoptosis, inhibits LPS (HY-D1056)-induced leukocyte cytokine release and cancer metastasis, and reduces CD44 expression on circulating CD3+ lymphocytes in cynomolgus monkeys. PF-03475952 can be used for the research of rheumatoid arthritis and hepatocellular carcinoma.

Tifuvirtide (T-1249) is a peptide human immunodeficiency virus type-1 (HIV-1) fusion inhibitor. Tifuvirtide is a synthetically designed hybrid retroviral envelope polypeptide. Tifuvirtide has antiretroviral activity. Tifuvirtide can be used for the research of HIV infection.

BI-1915, a chemical probe, is the selective inhibitor for Cathepsin S with an IC₅₀ of 17 nM. BI-1915 can be used in research of autoimmune diseases.

Anti-inflammatory agent 110 (Compound 7b) is a analgesic/anti-inflammatory agent. Anti-inflammatory agent 110 has a good binding affinity for COX-2. Anti-inflammatory agent 110 demonstrated potent analgesic and anti-inflammatory activities in the mouse hot plate test and the rat carrageenan edema model.

ATX inhibitor 15 (compound 30), a indole-based carbamate derivative, is a potent autotaxin (ATX) inhibitor with an IC₅₀ of 2.17 nM. ATX inhibitor 15 inhibits in vivo ATX and the gene expression of pro-fibrotic factors. ATX inhibitor 15 has lung protection effects in Bleomycin challenged mice lung fibrosis model.

Angiogenesis inhibitor 7 (compound BT2) ia a potent inhibitor of angiogenesis. Angiogenesis inhibitor 7 inhibits ERK phosphorylation, FosB/ΔFosB and VCAM-1 expression.

FASN-IN-6 (compound 44) is a potent fatty acid biosynthesis (FAB) inhibitor. FASN-IN-6 is an antibacterial agent with MICs of 1 μg/mL and 4 μg/mL for S. aureus ATCC 25923 and E. faecalis ATCC 29212, respectively.